IPD secures funding of €2.1M to initiate its first-in-human trials for prosthetic joint infections
PRESS RELEASE Amsterdam, July 20, 2023 IPD B.V. (Implant Preservation Devices), a Netherlands-based start-up specializing in the treatment of prosthetic joint infections, raised €2.1…
NLC and Australia’s BioCurate announce Strategic Alliance for Commercialization of New Therapies
Amsterdam, July 19, 2023 The two will collaborate on development projects to bring new therapies to market. NLC, the European Healthtech Venture Builder based…
NLC sluit eerste ronde van het NLC Health Impact Fund
PERSBERICHT 28 juni 2023 NLC, de grootste Healthtech Venture Builder van Europa, kondigt met trots de sluiting van de eerste investeringsronde van het NLC…
IN THE NEWS: HEALTH IMPACT FUND INITIAL CLOSE
Following the successful initial close of our flagship NLC Health Impact Fund, NLC is proudly featured in the news. Business and financial news outlets…
NLC announces it has completed the initial close of the NLC Health Impact Fund
June 26, 2023 40 high-impact ventures will receive investments from the largest European healthtech venture builder following the successful initial close of its flagship…